---
title: "港股異動 | 小米集團-W 現漲超 5% 小米 14 有望 11 月初面世 公司年內回購超 9 億港元"
description: "小米集團-W 現漲超 5%。截至發稿，漲 5.12%，報 12.32 港元，成交額 6.09 億港元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/98882492.md"
published_at: "2023-09-29T06:36:07.000Z"
---

# 港股異動 | 小米集團-W 現漲超 5% 小米 14 有望 11 月初面世 公司年內回購超 9 億港元

> 小米集團-W 現漲超 5%。截至發稿，漲 5.12%，報 12.32 港元，成交額 6.09 億港元。

智通財經 APP 獲悉，小米集團-W(01810) 現漲超 5%。截至發稿，漲 5.12%，報 12.32 港元，成交額 6.09 億港元。

消息面上，近日有關小米新一代旗艦小米 14 系列手機的相關爆料逐漸增多，而根據包括澎湃新聞在內多個媒體爆料表示，小米 14 很有可能會在 11 月首周面世。值得一提的是，近期多個消息源指出小米 14 的備貨量有望大幅提升達 60%。

此外，9 月 26 日，小米集團公告，回購股份 400 萬股，耗資 4674.92 萬港元。根據不完全統計，2023 年截至 9 月 26 日，小米集團年內合計耗資逾 9 億港元進行回購；公司近三年累計回購金額已超過 120 億港元。

### Related Stocks

- [01810.HK - 小米集團-W](https://longbridge.com/zh-HK/quote/01810.HK.md)
- [81810.HK - 小米集團-WR](https://longbridge.com/zh-HK/quote/81810.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Xiaomi's electric SUV tops China sales in January, sells twice as many as Tesla's Model Y | Xiaomi's YU7 electric SUV topped sales in China in January, selling 37,869 units, double that of Tesla's Model Y, which  | [Link](https://longbridge.com/zh-HK/news/275839815.md) |
| Xiaomi announces HK$2.5 billion buyback as competition and cost pressures weigh on stock | Xiaomi announced a stock buyback program worth up to HK$2.5 billion ($321 million), leading to a 2% rise in its shares.  | [Link](https://longbridge.com/zh-HK/news/273478227.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/zh-HK/news/276015719.md) |
| Mediterranean Tourism Investment FY Profit 1.6 Million Dinars | MEDITERRANEAN TOURISM INVESTMENT COMPANY PSC (MDTR.AM):MEDITERRANEAN TOURISM INVESTMENT FY NET PROFIT ATTRIBUTABLE 1.6 M | [Link](https://longbridge.com/zh-HK/news/275999518.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。